WO2004015113A3 - Albumin-fused ciliary neurotrophic factor - Google Patents

Albumin-fused ciliary neurotrophic factor Download PDF

Info

Publication number
WO2004015113A3
WO2004015113A3 PCT/EP2003/008710 EP0308710W WO2004015113A3 WO 2004015113 A3 WO2004015113 A3 WO 2004015113A3 EP 0308710 W EP0308710 W EP 0308710W WO 2004015113 A3 WO2004015113 A3 WO 2004015113A3
Authority
WO
WIPO (PCT)
Prior art keywords
albumin
neurotrophic factor
fused
ciliary neurotrophic
fragment
Prior art date
Application number
PCT/EP2003/008710
Other languages
French (fr)
Other versions
WO2004015113A2 (en
Inventor
Mathias Juers
Thomas Weimer
Hans-Peter Hauser
Darrell Sleep
Original Assignee
Aventis Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring Gmbh filed Critical Aventis Behring Gmbh
Priority to CA002496002A priority Critical patent/CA2496002A1/en
Priority to JP2004526896A priority patent/JP2005534330A/en
Priority to EP03750409A priority patent/EP1529108A2/en
Priority to AU2003271043A priority patent/AU2003271043A1/en
Publication of WO2004015113A2 publication Critical patent/WO2004015113A2/en
Publication of WO2004015113A3 publication Critical patent/WO2004015113A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a fusion protein comprising an albumin, or a fragment or a variant or a derivative thereof and at least one biologically active peptide or protein which activates the ciliary neurotrophic factor (CNTF) receptor, or a fragment or variant or a derivative thereof.
PCT/EP2003/008710 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor WO2004015113A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002496002A CA2496002A1 (en) 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor
JP2004526896A JP2005534330A (en) 2002-08-07 2003-08-06 Albumin fusion ciliary neurotrophic factor
EP03750409A EP1529108A2 (en) 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor
AU2003271043A AU2003271043A1 (en) 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40183302P 2002-08-07 2002-08-07
US60/401,833 2002-08-07

Publications (2)

Publication Number Publication Date
WO2004015113A2 WO2004015113A2 (en) 2004-02-19
WO2004015113A3 true WO2004015113A3 (en) 2004-05-06

Family

ID=31715745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008710 WO2004015113A2 (en) 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor

Country Status (6)

Country Link
EP (1) EP1529108A2 (en)
JP (2) JP2005534330A (en)
KR (1) KR20050065519A (en)
AU (1) AU2003271043A1 (en)
CA (1) CA2496002A1 (en)
WO (1) WO2004015113A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
DK2330200T3 (en) 2004-12-23 2017-07-24 Albumedix As GENE EXPRESSION TECHNIQUE
CN102462662A (en) * 2010-08-16 2012-05-23 重庆富进生物医药有限公司 Liposome-encapsulated recombinant human ciliary neurotrophic factor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719593A1 (en) * 1994-05-06 1995-11-10 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical composition containing them
WO1997024445A1 (en) * 1995-12-30 1997-07-10 Delta Biotechnology Limited Recombinant fusion proteins to growth hormone and serum albumin
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US20020039763A1 (en) * 2000-06-30 2002-04-04 Sheppard Paul O. Interferon-like protein Zcyto21

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719593A1 (en) * 1994-05-06 1995-11-10 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical composition containing them
WO1997024445A1 (en) * 1995-12-30 1997-07-10 Delta Biotechnology Limited Recombinant fusion proteins to growth hormone and serum albumin
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US20020039763A1 (en) * 2000-06-30 2002-04-04 Sheppard Paul O. Interferon-like protein Zcyto21

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200201, Derwent World Patents Index; Class B04, AN 2002-010886, XP002269916 *
DITTRICH F ET AL: "CILIARY NEUROTROPHIC FACTOR: PHARMACOKINETICS AND ACUTE-PHASE RESPONSE IN RAT", ANNALS OF NEUROLOGY, BOSTON, US, VOL. 35, NR. 2, PAGE(S) 151-163, ISSN: 0364-5134, XP002081357 *
PODUSLO J F AND CURRAN G L: "Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BNDF", MOLECULAR BRAIN RESEARCH, vol. 36, no. 2, 1996, pages 280 - 286, XP001179355 *
YEH P ET AL: "Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin -CD4 genetic conjugate", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, VOL. 89, NR. 5, PAGE(S) 1904-1908, ISSN: 0027-8424, XP002130704 *

Also Published As

Publication number Publication date
KR20050065519A (en) 2005-06-29
WO2004015113A2 (en) 2004-02-19
CA2496002A1 (en) 2004-02-19
JP2010213707A (en) 2010-09-30
AU2003271043A1 (en) 2004-02-25
EP1529108A2 (en) 2005-05-11
JP2005534330A (en) 2005-11-17

Similar Documents

Publication Publication Date Title
AU2003228809A1 (en) Kinase anchor protein muteins, peptides thereof, and related methods
EP2366713A3 (en) Polypeptide variants with altered effector function
ZA200308589B (en) Recombinant fusion proteins and the trimers thereof.
ZA200407868B (en) 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations.
WO2003004529A3 (en) Ephrin-tie receptor materials and methods
WO2005001025A3 (en) Immunoglobulin chimeric monomer-dimer hybrids
EG23318A (en) Substituted aromatic amide derivative, intermediate thereof agrohorticultural insecticide containingthereof and method for the use thereof.
WO2004009616A3 (en) Ghrelin analogs
DE60110683D1 (en) IgE-dependent histamine-releasing factor receptor, binding peptides, nucleic acids encoding them and their uses
EP1120464A3 (en) Stabilizing peptides, polypeptides and antibodies which include them
AU2003201727A1 (en) Recombinant protein expression
AU2002345804A1 (en) Antimicrobially active peptide
WO2004015113A3 (en) Albumin-fused ciliary neurotrophic factor
WO2005058953A3 (en) Ogh fusion polypeptides and therapeutic uses thereof
NO20026002L (en) A method for preparing a physiologically active IL-18 polypeptide
MXPA03007839A (en) Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity.
MY135452A (en) 2-methyl-thieno-benzodiazepine lyophilized formulation
AU6774198A (en) Human rab protein, srab
WO1999053064A3 (en) Methods of delivering glp-1
WO2001011937A3 (en) Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
MXPA03007384A (en) Emulsifiers, especially based on polyisobutylenamines.
AU2003285258A1 (en) Biologically active peptide conjugates
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
MXPA03006157A (en) Hormone replacement therapy method and its administration form.
AU2002241065A1 (en) Heterocarpine, a human GHRH-binding protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003271043

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2496002

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020057002155

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004526896

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003750409

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003750409

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057002155

Country of ref document: KR